These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 12034371)

  • 1. Metal-organic compounds: a new approach for drug discovery. N1-(4-methyl-2-pyridyl)-2,3,6-trimethoxybenzamide copper(II) complex as an inhibitor of human immunodeficiency virus 1 protease.
    Lebon F; Boggetto N; Ledecq M; Durant F; Benatallah Z; Sicsic S; Lapouyade R; Kahn O; Mouithys-Mickalad A; Deby-Dupont G; Reboud-Ravaux M
    Biochem Pharmacol; 2002 May; 63(10):1863-73. PubMed ID: 12034371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structural analysis of the copper(II) complexes of N2-(2-pyridylmethyl)-2-pyridinecarboxamide.
    Lebon F; Ledecq M; Dieu M; Demazy C; Remacle J; Lapouyade R; Kahn O; Durant F
    J Inorg Biochem; 2001 Sep; 86(2-3):547-54. PubMed ID: 11566326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases.
    Shi H; Liu K; Leong WW; Yao SQ
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3945-8. PubMed ID: 19328682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors.
    Hilgeroth A; Billich A; Lilie H
    Eur J Med Chem; 2001 Apr; 36(4):367-74. PubMed ID: 11461762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
    Adrian Meredith J; Wallberg H; Vrang L; Oscarson S; Parkes K; Hallberg A; Samuelsson B
    Eur J Med Chem; 2010 Jan; 45(1):160-70. PubMed ID: 19926360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization.
    Bouras A; Boggetto N; Benatalah Z; de Rosny E; Sicsic S; Reboud-Ravaux M
    J Med Chem; 1999 Mar; 42(6):957-62. PubMed ID: 10090778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 protease folding and the design of drugs which do not create resistance.
    Broglia R; Levy Y; Tiana G
    Curr Opin Struct Biol; 2008 Feb; 18(1):60-6. PubMed ID: 18160276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
    Dunn BM; Pennington MW; Frase DC; Nash K
    Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
    Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
    J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
    Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
    J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
    J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ternary dinuclear copper(II) complexes of a hydroxybenzamide ligand with diimine coligands: the 5,6-dmp ligand enhances DNA binding and cleavage and induces apoptosis.
    Ramakrishnan S; Shakthipriya D; Suresh E; Periasamy VS; Akbarsha MA; Palaniandavar M
    Inorg Chem; 2011 Jul; 50(14):6458-71. PubMed ID: 21671566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
    Sperka T; Pitlik J; Bagossi P; Tözsér J
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel strategies for targeting the dimerization interface of HIV protease with cross-linked interfacial peptides.
    Bowman MJ; Chmielewski J
    Biopolymers; 2002; 66(2):126-33. PubMed ID: 12325162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.
    Joshi A; Véron JB; Unge J; Rosenquist Å; Wallberg H; Samuelsson B; Hallberg A; Larhed M
    J Med Chem; 2013 Nov; 56(22):8999-9007. PubMed ID: 24160253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
    Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.